EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, JULY 8, 2021
Media advisory: The full article is linked to this news release.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2021.2675?guestAccessKey=a006b52c-6abf-414d-b0b9-b57946450d20&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=070821
What The Study Did: The SARS-CoV-2 BNT162b2 (Pfizer-BioNTech) vaccine appeared to be safe and achieve satisfactory serologic status in patients with cancer. While there was a lag in antibody production compared with the rate in the noncancer control group, seroconversion occurred in most patients after the second dose.
Authors: Irit Ben-Aharon, M.D., Ph.D., of the Rambam Health Care Campus in Haifa, Israel, is the corresponding author.
Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.